Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Gatifloxacin (GAT), a fourth-generation fluoroquinolone (FQ), is used to treat drug-resistant tuberculosis. Although DNA gyrase mutations are the leading cause of FQ resistance, mutations conferring resistance to GAT remain inadequately characterized. GAT-resistant mutants were selected from 7H10 agar plates containing 0.5 mg/L GAT (critical concentration). Mutations involved in GAT resistance were identified through whole-genome sequencing. In total, 123 isolates demonstrated resistance to GAT. Among these isolates, 55.3% (68/123) had gyrA gene mutations [G280A (D94N), A281G (D94G), G280T (D94Y) and G262T (G88C)]. The remainder (44.7%, 55/123) harboured gyrB gene mutations [A1495G (N499D), C1497A (N499K), C1497G (N499K) and A1503C (E501D)]. Mutations in the gyrA and gyrB genes are the main mechanisms of GAT resistance. These findings provide new insight into GAT resistance, and contribute to molecular diagnosis of GAT resistance in the clinical setting. Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.


Jing Bi, Qinglong Guo, Xiangdong Fu, Juan Liang, Lidong Zeng, Min Ou, Juanjuan Zhang, Zhaoqin Wang, Yicheng Sun, Lei Liu, Guoliang Zhang. Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021 Nov;112:189-194

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34547490

View Full Text